stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) EBITDA
Glaukos Corporation's EBITDA for fiscal 2025 was −$160.2M, compared with −$85.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$130.8M. Over the past ten years it has ranged from −$160.2M (fiscal 2025) to $9.2M (fiscal 2016) — the current reading is the lowest in ten years. Glaukos Corporation ranks 147th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$160.2M | — |
| FY2024 | −$85.8M | — |
| FY2023 | −$91.0M | — |
| FY2022 | −$44.3M | — |
| FY2021 | $4.0M | — |
| FY2020 | −$57.8M | — |
| FY2019 | −$36.7M | — |
| FY2018 | −$7.0M | — |
| FY2017 | $3.2M | (64.89%) |
| FY2016 | $9.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $10.6M | — |
| Jun 2026 | −$7.3M | — |
| Mar 2026 | −$7.2M | — |
| Dec 2025 | −$126.9M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $2.3B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| PEN Penumbra, Inc. compare | $209.4M |
| BRKR Bruker Corporation compare | $158.7M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
| GKOS Glaukos Corporation | −$130.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement